Placeholder

Comparative Effectiveness Research — Watch and Worry or Weigh In and Leverage?

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 2092. Categories: , .

Product Description

A little-publicized provision of the American Recovery and Reinvestment Act of 2009 is likely to have at least as big, if not a bigger, long-term impact on the pharmaceutical and medical device business as the recently passed Affordable Care Act. This provision allocated $1.1 billion for comparative effectiveness research (CER) — a mode of research that has been in place in many other countries for the past several decades. The stated goal of the CER program is to improve health outcomes based on evidence-based information. Other considerations include addressing the needs of populations traditionally underrepresented in clinical research and development of personalized medicine. CER studies are expected to be sufficiently powered to meet these needs. At the present time, the allocated funds are to be used for laying the foundation for such research, including the development of human and scientific capital, provision of data infrastructure, and dissemination of findings. Historically, the National Institutes of Health, the U.S. Department of Veterans Affairs, various state collaboratives, and payer organizations have funded public and private research projects that fit under the broader CER umbrella. Pharmaceutical…

Experts on this topic
Dr. Ramana Yalamanchili, Senior VP, Chief Clinical Strategist, HLS, part of Ogilvy CommonHealth
Mary Anderson, President, HLS, part of Ogilvy CommonHealth
Michael Zilligen, President, ProCom, part of Ogilvy CommonHealth

FEEDBACK